Perceval Plus sutureless surgical aortic heart valve is now available for commercial release in Europe.- LivaNova

LivaNova PLC a market-leading medical technology and innovation company, announced that the advanced Perceval Plus sutureless surgical aortic heart valve is now available for commercial release in Europe, having successfully completed a one-year limited launch with initial real-world clinical data gathering. Perceval Plus is positioned to become an essential component to any comprehensive heart program. Building on the clinically proven experience with Perceval, this next-generation valve facilitates minimally invasive cardiac surgery (MICS) and makes sutureless aortic valve replacement available to a wide patient population. Key innovations with Perceval Plus include the anticalcification treatment, FREE, for valve durability, along with design changes intended to improve patient outcomes. Perceval Plus is the next generation of Perceval, which is a trusted technology with 13 years of clinical use and more than 50,000 implants worldwide. Key benefits of Perceval Plus are: Designed for durability: The unique FREE anticalcification tissue treatment combines phospholipid reduction and aldehyde neutralization with aldehyde-free storage. Availability to a wide patient population: This valve is a versatile solution that can be used in complex or concomitant procedures and as a foundation for potential future Valve-in-Valve procedures. Facilitation of minimally invasive surgery: The truly sutureless surgical solution gives surgeons better visibility of the annulus and the anatomical structures. Designed to reduce permanent pacemaker implant (PPI) rates: Design enhancements, coupled with more efficient valve sizing, have been introduced with the goal of reducing pacemaker use.